Bamco Inc. NY Sells 27,157 Shares of IDEXX Laboratories, Inc. $IDXX

Bamco Inc. NY lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,032,620 shares of the company’s stock after selling 27,157 shares during the quarter. IDEXX Laboratories comprises about 3.0% of Bamco Inc. NY’s investment portfolio, making the stock its 7th biggest position. Bamco Inc. NY owned about 2.54% of IDEXX Laboratories worth $1,090,175,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of IDXX. National Pension Service lifted its position in shares of IDEXX Laboratories by 7.4% during the 1st quarter. National Pension Service now owns 126,400 shares of the company’s stock worth $53,082,000 after purchasing an additional 8,752 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in IDEXX Laboratories by 3.8% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 21,792 shares of the company’s stock worth $9,152,000 after buying an additional 800 shares during the period. Sit Investment Associates Inc. acquired a new position in shares of IDEXX Laboratories during the first quarter worth approximately $2,310,000. Lord Abbett & CO. LLC bought a new stake in shares of IDEXX Laboratories in the first quarter valued at approximately $1,316,000. Finally, Kovitz Investment Group Partners LLC boosted its position in shares of IDEXX Laboratories by 906.7% in the first quarter. Kovitz Investment Group Partners LLC now owns 17,759 shares of the company’s stock valued at $7,458,000 after acquiring an additional 15,995 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $704.20 on Friday. The company has a market capitalization of $56.23 billion, a price-to-earnings ratio of 55.84, a PEG ratio of 4.22 and a beta of 1.67. The company has a 50-day moving average of $683.23 and a 200-day moving average of $619.23. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.98% of the stock is owned by company insiders.

Analysts Set New Price Targets

IDXX has been the topic of a number of research reports. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 29th. Morgan Stanley upped their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Monday. Finally, UBS Group lifted their target price on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.